Pharmaceutical powerhouse Eli Lilly & Co. will buy Boston gene therapy maker Kelonia Therapeutics for at least $3.25 billion, the companies announced Monday. The acquisition will grant ...

Just a few months after ripping up the central nervous system-focused portion of its RIPK1 deal with Rigel Pharmaceuticals, Eli Lilly has now thrown out the rest of the pact too. Lilly notified Rigel ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. The Eli Lilly logo appears on a laptop computer screen in this photo illustration in Athens, ...

Eli Lilly & Co.’s new weight-loss pill Foundayo has gotten off to a sluggish start, according to new prescription data, an early sign of the challenge the drugmaker will have as it tries to catch up ...

Eli Lilly (LLY) on Monday announced an agreement to acquire Kelonia Therapeutics, a privately held cancer drug developer, in a deal worth up to $7B in cash, confirming a prior report from The Wall ...

Eli Lilly’s LLY3.07%increase; green up pointing triangle late-stage study of the efficacy and safety of a treatment for type 2 diabetes has produced positive results. Achieve-4, the longest phase 3 ...

Eli Lilly said it has agreed to acquire biotech company Kelonia Therapeutics. Lilly will pay $3.25 billion upfront and up to $7 billion in total, the company said. Kelonia is developing technology to ...

Investors often mistake share price for valuation. While Eli Lilly's stock price looks expensive on the surface, the company's underlying valuation metrics are quite modest. Eli Lilly stock might ...

Wall Street impressed with initial prescriptions for Lilly's Foundayo Lilly cautions early weekly figures may not be fully comprehensive Demand for Novo Nordisk's oral Wegovy also strong April 17 ...

Eli Lilly (LLY) is in advanced negotiations to acquire Kelonia Therapeutics in a transaction valued at more than $2 billion, The Wall Street Journal reported Sunday, citing people familiar with the ...

Eli Lilly is spending some of its GLP-1 money to buy up CAR-T gene therapy researchers. UBS analyst Michael Yee thinks that's smart strategy. So what does this Wall Street analyst like about Lilly?

Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for Kelonia Therapeutics and its phase 1-stage myeloma therapy. Kelonia is a lentiviral ...